Articles tagged "HLA antibodies"

2019 American Transplant Congress
Single Center Deceased Donor Renal Transplant (DDRTx) Outcomes in Sensitized Patients after Implementation of the Kidney Allocation System (KAS)
S. S. Patel, K. L. King, J. Kamal, E. Vasilescu, A. Husain, S. Mohan, L. E. Ratner, R. Crew
Columbia University Irving Medical Center, New York, NY
*Purpose: Introduction of KAS in 2014 prioritized access to DDRTx for highly-sensitized candidates although it was unclear whether the outcomes would be acceptable in this…
2019 American Transplant Congress
Report of 20 HLAMatchmaker Eplets Present on Denatured Class I HLA Molecules
R. de Marco¹, A. C. Lima², N. F. Pereira², M. Gerbase-DeLima¹
¹Immunogenetics Institute, AFIP, Sao Paulo, SP, Brazil, ²Immunogenetics Laboratory, Universidade Federal do Paraná, Curitiba, PR, Brazil
*Purpose: The purpose of this report is to describe 20 class I HLA eplets, herein called FakEplets, present on denatured HLA molecules.*Methods: The study included…
2019 American Transplant Congress
Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
S. C. Jordan¹, N. Ammerman¹, M. Toyoda², E. Huang¹, C. C. Nast³, A. Peng¹, S. Sethi¹, R. Najjar¹, I. Kim¹, K. Lim¹, J. Choi¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Department of Pathology, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…
2019 American Transplant Congress
Long Term Outcomes in Kidney Transplant Recipients Receiving Everolimus (EVR) or Mycophenolate (MPS) in Combination with Tacrolimus (TAC)
K. Ficher, C. Rosso Felipe, Y. Cardoso Dreige, K. Linhares, A. Ferreira Brígido, S. Stopa, L. Viana, M. Cristelli, P. Gessolo Lins, W. Aguiar, H. Proença, R. Marco, M. Gerbase de Lima, H. Tedesco Silva Junior, J. Medina Pestana
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Detailed long-term data comparing the use of EVR or MPS in kidney transplant recipients receiving TAC is lacking.*Methods: This is a 5-years extension analysis…
2019 American Transplant Congress
Improving Pre-Kidney Transplantion Laboratory Utilization in an Era of Increasing Waitlist Size
G. K. Mahowald¹, B. Kimball², N. Elias², E. Heher³, T. Girouard¹, S. L. Saidman¹, V. Pattanayak¹
¹Pathology, Massachusetts General Hospital, Boston, MA, ²Transplant Surgery, Massachusetts General Hospital, Boston, MA, ³Nephrology, Massachusetts General Hospital, Boston, MA
*Purpose: Beginning on March 25, 2015, our institution’s kidney transplant program has implemented a “readiness” protocol, whereby patients are listed after limited workup and comprehensive…
2018 American Transplant Congress
Epitope/Eplet Mismatch in Pediatric Renal Transplantation and Development of Donor Specific Antibody
R. George,¹ H. Sullivan,² R. Garro,¹ P. Winterberg,¹ B. Warshaw,¹ H. Gebel,² R. Bray.²
¹Pediatric Nephrology, Emory University & Children's Healthcare of Atlanta, Atlanta, GA; ²Dept. of Pathology, Emory Transplant Center, Emory University, Atlanta, GA.
Background: De-novo donor specific antibody (DSA) is one of the strongest independent predictors of graft loss with HLA mismatching being a major risk factor for…
2018 American Transplant Congress
Increasing the Donor Pool for Highly Sensitized Patients with Allele Specific Antibodies: Optimizing the Virtual Crossmatch (vXM)
A. Zhang,¹ Z. Zaky,² J. Africa,³ D. Good,¹ R. Bray,⁴ H. Gebel.⁴
¹Allogen Laboratories, Cleveland Clinic, Cleveland; ²Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland; ³Transplant Surgery, Charleston Area Medical Center, Charleston; ⁴Pathology & Laboratory Medicine, Emory University, Atlanta.
Background:Since implementation of the current Kidney Allocation System, highly sensitized patients with 98-100% cPRA (HSPs) are receiving ~10% of deceased donor kidneys compared to <2%…
2018 American Transplant Congress
Biopsy Correlates of DSA in Antibody-Mediated Rejection: C4d vs Microvascular Inflammation Scores
C. Harris, L. Anderson, R. Khaim, J. Choudhuri, R. Shapiro, S. Florman, F. Salem, M. Menon.
Icahn School of Medicine at Mount Sinai, New York, NY.
Background: The diagnosis of antibody-mediated rejection (AMR) requires the presence of both the histologic features of AMR as well as donor-specific antibodies (DSA). Whether anti-HLA…
2018 American Transplant Congress
Generation of Calculated Panel-Reactive Antibody Values Using a Reference Panel of Bone Marrow Donors
E. Kransdorf,¹ L. Gragert,^2,4 M. Pando,³ N. Kaur,² J. Patel,¹ I. Kim,¹ X. Zhang,¹ M. Maiers,⁴ J. Kobashigawa.¹
¹Cedars-Sinai Medical Center, Los Angeles, CA; ²Tulane University School of Medicine, New Orleans, LA; ³Baylor Scott & White, Temple, TX; ⁴National Marrow Donor Program, Minneapolis, MN.
Introduction: Calculated panel-reactive antibody (CPRA) is the official metric of sensitization used by the United Network for Organ Sharing (UNOS) for kidney allocation. The reference…
2018 American Transplant Congress
Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipients
S. Wan,^1,2 S. Chadban,^1,2 K. Wyburn.^1,2
¹Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Sydney Medical School, University of Sydney, Sydney, Australia.
BACKGROUND: Donor specific antibodies (DSA) have been implicated in the development of acute rejection (AR) and graft dysfunction in kidney transplant recipients (KTx). However, limited…